Literature DB >> 20153077

Cannabinoids and the immune system: an overview.

Radu Tanasescu1, Cris S Constantinescu.   

Abstract

Cannabinoids can influence the immune network. Data on the impact of exogenous cannabinoid ligands on immune function serve not only to understand how the endocannabinoid system modulates immune phenomena associated with infection or inflammation, but also to identify therapeutic targets for immune diseases. Cannabinoids can modulate immune reactions in the periphery but also in the brain, influence T cell subset balance and cytokine expression and play a role in the balance between neuroinflammation and neurodegeneration. Immune cells can synthesize endocannabinoids and also be influenced by cannabinoid analogues. Cannabinoid receptors show different expression on immune cells depending on activation status and stimuli. The complexity of relation between cannabinoid ligands of various classes and cannabinoid receptors brought the need to refine the simple conceptual frame of agonist-antagonists and offered potential implications for understanding interactions in pathological conditions. The immune influence of cannabinoid ligands is not fully elucidated. However, aspects of their immunomodulatory effects provide the basis for a context-dependent targeted therapeutic approach, thus leading to the possibility for the use of cannabinoids in the treatment of inflammatory disease. 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153077     DOI: 10.1016/j.imbio.2009.12.005

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  70 in total

1.  Response to Utomo et al.

Authors:  Robert W Isfort; Colm B Collins; Mark E Gerich
Journal:  Am J Gastroenterol       Date:  2015-08       Impact factor: 10.864

2.  Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells.

Authors:  Mireille Alhouayek; Linda Rankin; Sandra Gouveia-Figueira; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2018-02-05       Impact factor: 8.739

3.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

Review 4.  Risks associated with the non-medicinal use of cannabis.

Authors:  Eva Hoch; Udo Bonnet; Rainer Thomasius; Florian Ganzer; Ursula Havemann-Reinecke; Ulrich W Preuss
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

Review 5.  [Cannabis-induced disorders].

Authors:  M Soyka; U Preuss; E Hoch
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

Review 6.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

7.  Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Authors:  Monique Hinchcliff
Journal:  Arthritis Rheumatol       Date:  2020-07-04       Impact factor: 10.995

8.  Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

Authors:  Jessica M Sido; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

Review 9.  Building smart cannabis policy from the science up.

Authors:  Susan R B Weiss; Katia D Howlett; Ruben D Baler
Journal:  Int J Drug Policy       Date:  2017-02-08

10.  Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.

Authors:  Ewa Kozela; Nirit Lev; Nathali Kaushansky; Raya Eilam; Neta Rimmerman; Rivka Levy; Avraham Ben-Nun; Ana Juknat; Zvi Vogel
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.